📊 OM Key Takeaways
Is Outset Medical, Inc. (OM) a Good Investment?
Outset Medical is severely unprofitable with -$81.7M net losses on $119.5M revenue and negative operating cash flow of -$46.3M, creating critical cash runway concerns (~10 months at current burn rate with $35M cash on hand). While improving profitability trends (36.2% YoY improvement in net loss, 85.5% EPS improvement) and healthy 39.1% gross margins suggest operational progress, the company remains pre-profitable with -$66.7M operating loss and cannot service its $96.2M debt from operations.
Why Buy Outset Medical, Inc. Stock? OM Key Strengths
- Revenue growth of 5.1% YoY demonstrates market demand for products
- Gross margin of 39.1% indicates viable core product economics
- Profitability improving 36.2% YoY (losses shrinking), suggesting operational turnaround progress
- Strong liquidity ratios (6.67x current, 5.40x quick) provide near-term flexibility
OM Stock Risks: Outset Medical, Inc. Investment Risks
- Operating cash burn of $46.3M annually threatens solvency with only $35M cash (~10 months runway)
- Severe operating margin of -55.8% indicates R&D/SG&A expenses unsustainable relative to revenue base
- Cannot service $96.2M long-term debt from operations (negative interest coverage of -4.8x)
- Negative ROE (-64.3%) and ROA (-30.9%) destroying shareholder value
- Company dependent on capital raise, debt refinancing, or rapid profitability achievement for survival
Key Metrics to Watch
- Quarterly operating cash flow trajectory - critical metric given negative burn rate
- Gross margin sustainability and operating expense reduction as percentage of revenue
- Time to GAAP profitability and positive operating income
- Cash balance and runway calculation against burn rate
- Debt refinancing ability and covenant compliance
- Revenue growth acceleration relative to operating expense control
Outset Medical, Inc. (OM) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 6.67x current ratio provides a solid financial cushion.
OM Profit Margin, ROE & Profitability Analysis
OM vs Healthcare Sector: How Outset Medical, Inc. Compares
How Outset Medical, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Outset Medical, Inc. Stock Overvalued? OM Valuation Analysis 2026
Based on fundamental analysis, Outset Medical, Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Outset Medical, Inc. Balance Sheet: OM Debt, Cash & Liquidity
OM Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Outset Medical, Inc.'s revenue has grown significantly by 27% over the 5-year period, indicating strong business expansion. The most recent EPS of $-52.28 indicates the company is currently unprofitable.
OM Revenue Growth, EPS Growth & YoY Performance
OM Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $28.7M | -$17.8M | $-1.00 |
| Q2 2025 | $27.4M | -$18.5M | $-1.04 |
| Q1 2025 | $28.2M | -$25.8M | $-3.66 |
| Q3 2024 | $28.7M | -$27.9M | $-0.55 |
| Q2 2024 | $27.4M | -$34.5M | $-0.66 |
| Q1 2024 | $28.2M | -$39.9M | $-0.78 |
| Q3 2023 | $27.8M | -$36.9M | $-0.85 |
| Q2 2023 | $25.1M | -$36.9M | $-0.90 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Outset Medical, Inc. Dividends, Buybacks & Capital Allocation
OM SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Outset Medical, Inc. (CIK: 0001484612)
📋 Recent SEC Filings
❓ Frequently Asked Questions about OM
What is the AI rating for OM?
Outset Medical, Inc. (OM) has an AI rating of SELL with 76% confidence, based on fundamental analysis of SEC EDGAR filings.
What are OM's key strengths?
Claude: Revenue growth of 5.1% YoY demonstrates market demand for products. Gross margin of 39.1% indicates viable core product economics.
What are the risks of investing in OM?
Claude: Operating cash burn of $46.3M annually threatens solvency with only $35M cash (~10 months runway). Severe operating margin of -55.8% indicates R&D/SG&A expenses unsustainable relative to revenue base.
What is OM's revenue and growth?
Outset Medical, Inc. reported revenue of $119.5M.
Does OM pay dividends?
Outset Medical, Inc. does not currently pay dividends.
Where can I find OM SEC filings?
Official SEC filings for Outset Medical, Inc. (CIK: 0001484612) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is OM's EPS?
Outset Medical, Inc. has a diluted EPS of $-5.37.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is OM a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Outset Medical, Inc. has a SELL rating with 76% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is OM stock overvalued or undervalued?
Valuation metrics for OM: ROE of -64.3% (sector avg: 15%), net margin of -68.3% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy OM stock in 2026?
Our dual AI analysis gives Outset Medical, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is OM's free cash flow?
Outset Medical, Inc.'s operating cash flow is $-46.3M, with capital expenditures of $798.0K. FCF margin is -39.4%.
How does OM compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -68.3% (avg: 12%), ROE -64.3% (avg: 15%), current ratio 6.67 (avg: 2).